Cargando…

Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors

BACKGROUND: Glioblastoma is a fatal disease despite aggressive multimodal therapy. PD-1 blockade, a therapy that reinvigorates hypofunctional exhausted CD8 T cells (T(ex)) in many malignancies, has not shown efficacy in glioblastoma. Loss of CD4 T cells can lead to an exhausted CD8 T-cell phenotype,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Saad M, Desai, Rupen, Coxon, Andrew, Livingstone, Alexandra, Dunn, Gavin P, Petti, Allegra, Johanns, Tanner M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772691/ https://www.ncbi.nlm.nih.gov/pubmed/36543376 http://dx.doi.org/10.1136/jitc-2022-005293

Ejemplares similares

CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell
por: Wang, Binglin, et al.
Publicado: (2021)

Type 17 immunity promotes the exhaustion of CD8(+) T cells in cancer
por: Kim, Byung-Seok, et al.
Publicado: (2021)

4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39(+) CD8 T cells from primary and metastatic sites of epithelial ovarian cancers
por: Leem, Galam, et al.
Publicado: (2020)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3(+) and CD8(+) T cell density and predict prognosis in hepatocellular carcinoma
por: Nicolè, Lorenzo, et al.
Publicado: (2022)

Correction: Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
Publicado: (2023)

Single-cell sequencing on CD8(+) TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer
por: Komuro, Hiroyasu, et al.
Publicado: (2023)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer
por: Shen, Yang, et al.
Publicado: (2020)

Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation
por: Qin, Rui, et al.
Publicado: (2021)

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
por: Dey, Souvik, et al.
Publicado: (2020)

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
por: Yang, Rui, et al.
Publicado: (2020)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
por: Banchereau, Romain, et al.
Publicado: (2021)

Reactivation of low avidity tumor-specific CD8(+) T cells associates with immunotherapeutic efficacy of anti-PD-1
por: Sugiyarto, Gessa, et al.
Publicado: (2023)

TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8(+) T cell and XCR1(+) dendritic cell spatial co-localization
por: Gardner, Alycia, et al.
Publicado: (2022)

CD8(+)CD57(+) T cells exhibit distinct features in human non-small cell lung cancer
por: Huang, Bing, et al.
Publicado: (2020)

PD-1(+)CXCR5(−)CD4(+) Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma
por: Li, Jiang-Ping, et al.
Publicado: (2021)

Single-Cell Analysis Reveals a CD4(+) T-cell Cluster That Correlates with PD-1 Blockade Efficacy
por: Kagamu, Hiroshi, et al.
Publicado: (2022)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Saponin-based adjuvants enhance antigen cross-presentation in human CD11c(+) CD1c(+) CD5(−) CD163(+) conventional type 2 dendritic cells
por: Ho, Nataschja I, et al.
Publicado: (2023)

Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
por: Zhang, Cangang, et al.
Publicado: (2021)

Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
por: Church, Candice, et al.
Publicado: (2022)

CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma
por: Lai, Chester, et al.
Publicado: (2021)

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
por: Martins Nascentes Melo, Luiza, et al.
Publicado: (2023)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden
por: van den Bulk, Jitske, et al.
Publicado: (2023)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

IFN-γ treatment protocol for MHC-I(lo)/PD-L1(+) pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential
por: Stifter, Katja, et al.
Publicado: (2020)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56(bright)CD16(−) subset
por: Veneziani, Irene, et al.
Publicado: (2022)

Delayed vaccine-induced CD8(+) T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication
por: van der Sluis, Tetje C, et al.
Publicado: (2023)

DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma
por: Fitzgerald, Allison A, et al.
Publicado: (2021)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
por: Duurland, Chantal L, et al.
Publicado: (2022)

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
por: Park, Miso, et al.
Publicado: (2023)

Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion
por: Song, Byong-Sop, et al.
Publicado: (2022)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells
por: Balança, Camille-Charlotte, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q9d1ksn46888gk9751gmg8fn3h